摘要
目的分析小儿支气管哮喘患者治疗前、后血清基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶组织抑制剂-1(TIMP-1)、白细胞介素-18(IL-18)及免疫球蛋白E(IgE)水平变化,并探讨联合检测各项指标对疾病预判及疗效观察的临床应用价值。方法选取92例小儿支气管哮喘患者(观察组)及30例小儿健康体检者(对照组)为研究对象,采用酶联免疫法(ELISA)检测对照组及观察组治疗前后血清MMP-9、TIMP-1、IL-18、IgE水平。结果观察组血清MMP-9、TIMP-1、IL-18、IgE水平明显高于对照组(P<0.01);观察组治疗后血清MMP-9、TIMP-1、IL-18、IgE水平较治疗前明显降低(P<0.01);支气管哮喘患儿血清MMP-9、TIMP-1、IL-18、IgE水平与患儿性别无关(P>0.05),与病程长短、病情轻重及治疗效果明显相关(P均<0.05)。结论血清MMP-9、TIMP-1、IL-18、IgE与小儿支气管哮喘密切相关,其血清水平变化对哮喘病情及疗效评估具有指导意义,为新的临床治疗靶点提供理论依据。
Objective To investigate the clinical value of combined detection of MMP-9, TIMP-1, IL-18 and IgE in children with bronchial asthma. Methods 92 asthmatic children and 30 healthy children were divided into study group and control group separately. ELISA was adopted to measure the levels of MMP-9, TIMP-1, IL-18 and IgE in the serum. Results The serum levels of MMP-9, TIMP-1, IL-18 and IgE were significantly higher than that of control group. There were significant difference before and after treatment（P＆lt;0.01）. No significant correlation was found between expression of MMP-9, TIMP-1, IL-18, IgE and sex structure（P＆gt;0.05）. Course of the disease and illness severity could affect the expression of MMP-9, TIMP-1, IL-18, IgE（P＆lt;0.05）. Conclusion There are closely relation between them. The level of MMP-9, TIMP-1, IL-18, IgE in serum can guide asthma condition assessment, provide theory basis for new clinical therapeutic targets.
出处
《中华临床医师杂志（电子版）》
CAS
2014年第18期39-42,共4页
Chinese Journal of Clinicians(Electronic Edition)
